Express Scripts, CVS Formulary Updates: Who's In, Who's Out?
This article was originally published in Scrip
Express Scripts and CVS/Caremark, two US pharmacy benefit managers (PBMs) that have been increasingly vocal about high drug prices, have revised their formularies for 2016 and cut dozens of brand-name therapies from the lists of pharmaceutical products that they will cover on behalf of their health plan clients.
You may also be interested in...
The pharmacy benefit manager says it has been able to negotiate a discount with Gilead enabling it to give both Harvoni and AbbVie’s Viekira Pak preferred formulary placement. Express Scripts also is expanding its indication-based oncology management initiative.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.